[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"brand-innovent":3},{"head":4,"company":39,"invest":44,"children":45,"shops":46,"category":47,"sameIndustry":5,"rid":6},{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"brandId":6,"brandLogo":7,"brandImage":5,"brandName":8,"webName":9,"balias":5,"enterId":10,"mainindustry":11,"industry":5,"brandType":5,"brandHonor":5,"brandTel":12,"establishdate":13,"brandBirth":14,"cityarea":5,"brandWebsite":5,"brandSobp":5,"brandVisit":5,"totalVisits":15,"status":16,"isDeleted":16,"comment":5,"remark":5,"logoExistStatus":17,"imageExistStatus":17,"industryId":5,"industryRanking":5,"score":5,"enterName":18,"mallShopList":19,"brandSummary":20,"likes":5,"unlikes":5,"follow":5,"pagetitle":21,"pagekeywords":22,"pagedesc":23,"brandContent":24,"province":5,"city":5,"area":5,"detailaddress":25,"unifiedscc":26,"enterType":27,"enterLegalperson":28,"enterStablishdate":29,"regauthority":30,"licenseValidity":31,"approvaldate":32,"regcapital":33,"incapital":34,"businessscope":35,"ownBrand":5,"enterTelphone":12,"enterWebsite":36,"business":37,"enterQq":5,"enterMail":38,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"regtrademark":5},null,"64336","\u002Fprofile\u002Fupload\u002F2025\u002F01\u002F25\u002Fbd8ceddeeef6ee68427f49ed27a11962.gif","信达生物Innovent","innovent",56838,10006,"0512-69566088","2011年","苏州市",856,0,"1","信达生物制药（苏州）有限公司",[],"成立于2011年，致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物的上市企业，建立了一条覆盖肿瘤、代谢疾病、自身免疫等多个疾病领域的新药品种产品链，其中有10余个产品已获批上市，凭借过硬的科研实力和优异的ESG表现，已成为全国生物制药行业的佼佼者。","信达医药品牌简介_信达生物制药怎么样→品牌之家","信达生物制药,信达抗癌药物,信达医药,信达药品,信达药业","信达药业品牌简介，品牌之家为您推荐信达制药品牌历程、产品价格、口碑评价等内容。","成立于2011年，致力于开发、生产和销售用于治疗肿瘤等重大疾病的创新药物的香港联交所上市企业，建立了一条覆盖肿瘤、代谢疾病、自身免疫等多个疾病领域的新药品种产品链，其中有多个产品已获批上市\n\n信达生物成立于2011年，致力于开发、生产和销售用于治疗肿瘤等重大疾病的创新药物。2018年10月31日，信达生物制药在香港联交所主板挂牌上市，股票代码：01801。\n\n自成立以来，公司凭借创新成果和国际化的运营模式在众多生物制药公司中脱颖而出。建立起了一条包括34个新药品种的产品链，覆盖肿瘤、代谢疾病、自身免疫等多个疾病领域，其中7个品种入选国家“重大新药创制”专项。公司已有7个产品（信迪利单抗注射液，商品名：达伯舒®，英文商标：TYVYT®；贝伐珠单抗生物类似药，商品名：达攸同®，英文商标：BYVASDA®；阿达木单抗生物类似药，商品名：苏立信®，英文商标：SULINNO®；利妥昔单抗生物类似药，商品名：达伯华®，英文商标：HALPRYZA®；pemigatinib口服抑制剂，商品名：达伯坦®，英文商标：PEMAZYRE®；奥雷巴替尼，商品名：耐立克®；雷莫西尤单抗，商品名：希冉择®，英文商标：CYRAMZA®）获得批准上市，3个品种在NMPA审评中，4个新药分子进入III期或关键性临床研究，另外还有20个新药品种已进入临床研究。\n\n目前，公司按照NMPA、美国FDA和欧盟EMA的GMP标准建成了高端生物药产业化基地。产业化生产线已通过合作方国际制药集团对产业化生产要求的GMP审计。公司已组建了一支具有国际先进水平的高端生物药开发、产业化人才团队，其中包括100多位海归专家。公司立足自主创新的产品与美国礼来制药集团在多个领域建立战略合作，总金额超25亿美金，信达生物将中国创新产品引入全球市场。\n\n“始于信，达于行”，开发出老百姓用得起的高质量生物药，是信达生物的理想和目标。","苏州工业园区东平街168号","9132059458102064XX","有限责任公司(外商投资、非独资)","旦巧荣","2011-08-24","苏州工业园区市场监督管理局","2011-08-24 至 2051-08-21","2024-03-29","15,946.475万(美元)","15,246.475万(美元)","研发、生产抗体类及蛋白类药物、药品、生物医药制品，从事上述产品的销售及进出口业务，并提供相关技术转让、技术咨询和技术服务。（依法须经批准的项目，经相关部门批准后方可开展经营活动）\n一般项目：进出口代理（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）","www.innoventbio.net","医药制造业","info@innoventbio.com",{"enterId":40,"enterName":18,"province":5,"city":5,"area":5,"detailaddress":25,"unifiedscc":26,"enterType":27,"enterLegalperson":28,"enterStablishdate":29,"regauthority":30,"licenseValidity":31,"approvaldate":32,"regcapital":33,"incapital":34,"businessscope":35,"ownBrand":5,"enterTelphone":12,"enterWebsite":36,"business":37,"performance":41,"socialSecurity":42,"registrationNumber":43,"enterQq":5,"enterMail":38,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"status":16,"regtrademark":5,"remark":5},"56838","开业","1239人","320594400030063",{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"id":5,"brandId":5,"brandName":5,"busmodel":5,"franchiseFund":5,"totalStores":5,"devmodel":5,"franchiseIndustry":5,"investmenttel":5,"suitablePeople":5,"state":5},[],[],[48],{"createTime":49,"updateTime":50,"createBy":5,"updateBy":5,"industryId":51,"webId":5,"industryName":52,"industryAlias":5,"industryIcon":5,"industryTrans":53,"pageTitle":54,"pageDesc":55,"pageKeywords":56,"mainTitle":57,"pageSubtitle":58,"indSummary":59,"industryLevel":60,"parentId":61,"parentName":5,"sortOrder":62,"status":16,"classifyVisit":5,"totalVisits":63,"searchName":5,"starLevel":5,"limit":5},"2000-01-01 00:00:00","2026-06-16 16:50:00","10006","生物科技","\u002Fprofile\u002Fupload\u002F2023\u002F11\u002F08\u002F19f46e89d8cd077b73c7adb33bb2b59f.png","生物科技公司十大排行榜-国内知名生物科技公司有哪些-ZGALL品牌榜","2026年十大生物科技公司排行榜最新发布，生物科技公司十大排行榜前十名有中国生物、中国生物制药、百济神州、恒瑞、豪森药业、百利天恒、康方、复星医药、石药、信达。生物科技十大品牌排行榜由品牌研究部门收集整理大数据分析研究得出，帮助你了解中国生物科技公司有哪些。","生物科技公司排名前十有哪些,中国生物科技公司排名前十,生物科技有限公司排名,中国生物科技公司排名,全国生物科技公司排名","生物科技品牌排行榜","2026生物科技公司，生物制药公司排行榜，国内生物医药科技公司有哪些","生物科技哪个好？品牌TOP榜权威发布2026年生物科技名录；居前十的有：中国生物CNBG、中国生物制药、百济神州BeiGene、恒瑞医药、豪森药业、百利天恒、康方Akesobio、复星医药、石药CSPC、信达生物Innovent等，【行业品牌名录】基于大数据与人工智能技术，整合300+国际权威榜单及企业申报数据，通过算法分析市场占有率、创新力等12项指标，并解析超百万条舆情信息，采用加权模型（算法60%+专家30%+用户10%）生成动态排名。数据月度更新，申报需通过ISO认证审核，排名不分先后，仅供参考。",3,1411,99,589]